X

Drug Profile

RDEA 436

Alternative Names: RDEA436

Latest Information Update: 19 Jul 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Valeant Pharmaceuticals International
Developer Ardea Biosciences
Class Anti-inflammatories; Antineoplastics; Small molecules
Mechanism of Action Mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Cancer; Inflammation

Most Recent Events

13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
28 Apr 2009 RDEA 436 licensed to Bayer HealthCare worldwide ,
16 Apr 2008 Phase-0 for Cancer in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com